These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17626754)

  • 21. Prognostic significance of Bcl-2 and Bax protein expression in the patients with oral squamous cell carcinoma.
    Zhang M; Zhang P; Zhang C; Sun J; Wang L; Li J; Tian Z; Chen W
    J Oral Pathol Med; 2009 Mar; 38(3):307-13. PubMed ID: 18710422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation between prognosis and cell proliferation, apoptosis in squamous cell carcinoma of tongue].
    Yang YP; Qing HY; Cao Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2003 Jan; 38(1):31-4. PubMed ID: 12760773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
    Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
    Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological indicators of aggressiveness in T1 ductal invasive breast cancer.
    Bucci B; Carico E; Rinaldi A; Froio F; Puce YM; D'Agnano I; Vecchione A; Brunetti E
    Anticancer Res; 2001; 21(4B):2949-55. PubMed ID: 11712792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Annexin A3 is associated with a poor prognosis in breast cancer and participates in the modulation of apoptosis in vitro by affecting the Bcl-2/Bax balance.
    Zeng C; Ke Z; Song Y; Yao Y; Hu X; Zhang M; Li H; Yin J
    Exp Mol Pathol; 2013 Aug; 95(1):23-31. PubMed ID: 23631820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
    Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
    BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
    Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
    Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.
    Kato T; Kameoka S; Kimura T; Nishikawa T; Kobayashi M
    Anticancer Res; 2002; 22(2B):1097-103. PubMed ID: 12168907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Significance of TIMP-1 and nm-23 expressions in HER-2-positive breast cancer].
    Liu J; Yang YF; Fu XL; Yu Y; Gu L
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):600-4. PubMed ID: 23158994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas.
    Kato K; Kawashiri S; Yoshizawa K; Kitahara H; Yamamoto E
    J Oral Pathol Med; 2008 Jul; 37(6):364-71. PubMed ID: 18410312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of PCNA, p53, Bax, and Bcl-X in oral poorly differentiated and basaloid squamous cell carcinoma: relationships with prognosis.
    Sampaio-Góes FC; Oliveira DT; Dorta RG; Nonogaki S; Landman G; Nishimoto IN; Kowalski LP
    Head Neck; 2005 Nov; 27(11):982-9. PubMed ID: 16136583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome.
    Tsamandas AC; Kardamakis D; Petsas T; Zolota V; Vassiliou V; Matatsoris T; Kalofonos H; Vagianos CE; Scopa CD
    In Vivo; 2007; 21(1):113-8. PubMed ID: 17354623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
    Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
    Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.